Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients

Ähnliche Einträge

• BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis
  von: Camille Kockerols, et al.
  Veröffentlicht: (2024)
• Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real‐world analysis from the PETHEMA registry
  von: Juan M. Alonso‐Dominguez, et al.
  Veröffentlicht: (2026)
• Treatment‐Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients
  von: C. Kockerols, et al.
  Veröffentlicht: (2025)
• Unveiling the nephrotoxic profile of BCR‐ABL tyrosine kinase inhibitors: A real‐world experience in Africa
  von: Zekarias Seifu Ayalew, et al.
  Veröffentlicht: (2024)
• Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
  von: Takeshi Kondo, et al.
  Veröffentlicht: (2024)